A Genetic Screen Identifies TCF3/E2A and TRIAP1 as Pathway-Specific Regulators of the Cellular Response to p53 Activation  by Andrysik, Zdenek et al.
Cell Reports
ReportA Genetic Screen Identifies TCF3/E2A
and TRIAP1 as Pathway-Specific Regulators
of the Cellular Response to p53 Activation
Zdenek Andrysik,1 Jihye Kim,2 Aik Choon Tan,2 and Joaquı´n M. Espinosa1,*
1Howard Hughes Medical Institute & Department of Molecular, Cellular and Developmental Biology, University of Colorado at Boulder,
Boulder, CO 80309, USA
2Department of Medicine/Medical Oncology, University of Colorado at Denver Anschutz Medical Campus, Aurora, CO 80045, USA
*Correspondence: joaquin.espinosa@colorado.edu
http://dx.doi.org/10.1016/j.celrep.2013.04.014SUMMARY
The p53 transcription factor participates in diverse
cellular responses to stress, including cell-cycle
arrest, apoptosis, senescence, and autophagy.
The molecular mechanisms defining the ultimate
outcome of p53 activation remain poorly character-
ized. We performed a genome-wide genetic screen
in human cells to identify pathway-specific coregu-
lators of the p53 target gene CDKN1A (p21), an in-
hibitor of cell-cycle progression, versus BBC3
(PUMA), a key mediator of apoptosis. Our screen
identified numerous factors whose depletion cre-
ates an imbalance in the p21:PUMA ratio upon
p53 activation. The transcription factor TCF3, also
known as E2A, drives p21 expression while re-
pressing PUMA across cancer cell types of multiple
origins. Accordingly, TCF3/E2A depletion impairs
the cell-cycle-arrest response and promotes
apoptosis upon p53 activation by chemothera-
peutic agents. In contrast, TRIAP1 is a specific
repressor of p21 whose depletion slows down
cell-cycle progression. Our results reveal strategies
for driving cells toward specific p53-dependent re-
sponses.INTRODUCTION
The p53 transcription factor functions as a signaling hub during
the cellular response to stress. p53 is activated by various
signaling cascades elicited by myriad stress stimuli, including
oncogene hyperactivation, DNA damage, and nutrient depriva-
tion (Vousden and Prives, 2009). These signaling pathways
relieve the inhibitory effects of the p53 repressors MDM2 and
MDM4, which otherwise target p53 for proteasomal degrada-
tion and mask its transactivation domain. Upon activation,
p53 induces transcription of genes involved in varied cellular re-
sponses such as cell-cycle arrest, apoptosis, senescence, and
autophagy (Riley et al., 2008). Although many p53 target genes
participating in each pathway have been identified, the mecha-1346 Cell Reports 3, 1346–1354, May 30, 2013 ª2013 The Authorsnisms defining which cellular response is adopted remain
poorly characterized. A thorough understanding of these mech-
anisms of cell-fate choice will be required for the effective
deployment of p53-based therapies in the clinic. Currently,
small molecule inhibitors of MDM2 and MDM4 are being tested
in clinical trials for cancer treatment (Brown et al., 2009). How-
ever, the cellular response elicited by these compounds varies
greatly across cancer cell types (Parı´s et al., 2008; Sullivan
et al., 2012b; Tovar et al., 2006). Thus, the identification of fac-
tors that regulate cell-fate choice upon p53 activation would
reveal strategies to enhance the therapeutic application of
these drugs.
Many efforts in the p53 field have been devoted to the charac-
terization of p53 posttranslational modifications and p53 cofac-
tors as well as p53-autonomous mechanisms driving gene-spe-
cific regulation within the p53 transcriptional program (Vousden
and Prives, 2009). With the advent of functional genomics, it is
now possible to perform genetic screens in human cells for the
unbiased identification of pathway-specific coregulators of p53
target genes. We report here the results of a genome-wide short
hairpin RNA (shRNA) genetic screen to identify factors that regu-
late the expression ratio between CDKN1A (p21), one of the key
mediators of p53-dependent cell-cycle arrest, and BBC3
(PUMA), a BH3-only protein that mediates much of the apoptotic
effects of p53. Using a flow cytometry assay to isolate cells with
altered expression of the endogenous p21 and PUMA proteins
and a DNA deep-sequencing protocol to identify the shRNAs ex-
pressed in these cells, we found numerous factors that affect the
p21:PUMA ratio. Most prominent among these was TCF3 (tran-
scription factor 3, also known as E2A), a basic helix-loop-helix
(bHLH) DNA binding protein that is required for p21 induction,
yet functions as a repressor of PUMA. Depletion of TCF3/E2A
leads to lower p21 accumulation and higher PUMA expression
across cancer cell types of diverse tissue origin, thus promoting
the apoptotic response upon p53 activation. Additionally, we
identified TRIAP1 (TP53-regulated inhibitor of apoptosis, also
known as p53 cell survival factor or p53CSV) as a gene-specific
repressor of p21. TRIAP1 knockdown leads to augmented p21
expression before and during p53 activation and slows down
cell proliferation. Overall, our research identified multiple factors
that function as gene-specific coregulators within the p53
network and reveals several strategies to manipulate the cellular
response upon p53 activation.
Figure 1. A Genome-wide shRNA Screen Identifies Pathway-Specific Regulators within the p53 Network
(A) Western blot assays showing that activation of p53 with Nutlin-3 leads to concurrent induction of p21 and PUMA in HCT116 cells.
(B) Hypothetical factors W, X, Y, and Z function as gene-specific coregulators of p21 and PUMA.
(C) Experimental design for shRNA screen leading to identification of gene-specific coregulators of p21 and PUMA.
(D) Heatmaps showing differential counts of shRNAs in the sorted populations dubbed P1 (high p21:PUMA ratio) and P2 (low p21:PUMA ratio) versus the total
population. Numbers represent the shRNA count in the three sets of triplicates.
(E) Different shRNAs against TCF3/E2A and TRIAP1 change the p21:PUMA expression ratio as predicted by the genetic screen. TCF3/E2A depletion reduces p21
expression and increases PUMA expression without affecting p53 accumulation. TRIAP1 knockdown leads to increased p21 expressionwith no effects on PUMA
or p53 accumulation.
See also Figure S1.RESULTS
AGenetic Screen in HumanCells for the Identification of
Factors Regulating the p21:PUMA Expression Ratio
upon p53 Activation
p53 activation commonly leads to concurrent induction of target
genes in distinct functional pathways, yet the precise cellular
response adopted varies widely across cell types. In HCT116
colorectal cancer cells, p53 activationwithNutlin-3, a smallmole-
cule inhibitor of the p53-MDM2 interaction, leads to strong induc-
tion of both p21 and PUMA (Figure 1A). In this scenario, HCT116Ccells undergo cell-cycle arrest, but become highly sensitized to
additional apoptotic stimuli (Henry et al., 2012; Sullivan et al.,
2012b). We hypothesized the existence of pathway-specific cor-
egulators with the ability to control the p21:PUMA expression
ratio in this setting and thus affect the cell-fate choice upon p53
activation (factorsW,X,Y, andZ inFigure 1B). Thesecoregulators
would function asgene-specific coactivators or repressors of p21
or PUMA. According to this hypothesis, whereas an shRNA
against factors X or Y would lead to a greater p21:PUMA expres-
sion ratio, an shRNA against factors W or Z would decrease this
ratio (Figure 1B). In order to identify these factors, we designedell Reports 3, 1346–1354, May 30, 2013 ª2013 The Authors 1347
a genome-wide shRNA screen as depicted in Figure 1C. First, we
transduced a lentiviral shRNA library targeting >16,000 human
genes (SBI library) into HCT116 cells. After antibiotic selection
of stable integrants and clearance of cells carrying shRNAs
against essential genes during 2 weeks of culture, we activated
p53 with Nutlin-3 and isolated cells expressing different ratios of
endogenous p21 and PUMA by fluorescence activated cell sort-
ing (FACS). After intensive testing of multiple fixation/staining
conditions and antibodies, we obtained a protocol that robustly
detects a p53-dependent increase in the levels of the endoge-
nous p21 and PUMA proteins by flow cytometry (Figures S1A
and S1B; see the Extended Experimental Procedures), which
enabled us to sort cells with varying p21:PUMA ratios during the
screen. Whereas the population dubbed P1 stained strongly for
p21 and weakly for PUMA, the P2 population stained strongly
for PUMA and weakly for p21. We then isolated DNA from P1,
P2, and the input population (total) and amplified shRNAs by
PCR with primers against the flanking sequences. In a nested
PCR, we tagged the shRNA cassettes for Illumina deep
sequencing and sequenced three biological replicates of each
population.UsingabioinformaticspipelinedubbedBiNGS (Bioin-
formatics for Next Generation Sequencing) (Kim and Tan, 2012),
we identified shRNAs whose abundance was significantly
different between P1 versus total and P2 versus total (Figure 1D).
Of note, we foundmany shRNAs that fell below the level of detec-
tion in the total population yet couldbecountedhundredsof times
in either P1 or P2. Importantly, BiNGS takes into account how
many shRNAs against a given messenger RNA (mRNA) display
the same behavior, a concept dubbed ‘‘reagent redundancy’’ in
RNA interference (RNAi) screens, which reduces the chances of
false positives due to ‘‘off-target’’ effects of individual shRNAs
(Echeverri et al., 2006). The information on shRNA multiplicity is
then condensed into a p(wZ) value for each gene (Figure S1C)
(see the Extended Experimental Procedures for details). Using a
cutoff of p(wZ) < 0.01, we identified 491 candidate genes whose
knockdown would create an increase in the p21:PUMA ratio
and523candidategenesexerting theoppositeeffect (FigureS1C;
Table S1). Next, we selected40 candidate genes in each cate-
gory for validationandestablished stable knockdowns inHCT116
cells for eachof them (see theExtendedExperimentalProcedures
for selection criteria; Table S2). Importantly, during these valida-
tion efforts we utilized shRNAs from a different library (TRC, The
RNAi Consortium). Since the seed sequences in the TRC shRNAs
are different from those in the SBI shRNAs used in the initial
screen, this exercise significantly increased our confidence in
positively validated results. In order to test the effect of the 81 in-
dividual knockdowns on the p21:PUMA ratio, we employed a
dual-fluorescence western blot assay that enabled us to monitor
p21 and PUMA protein expression within the same blot (see
example in Figure S1D). Because this assay bypasses the fixation
steps involved in the flow cytometry assay used for the screen,
which could potentially create artifacts, it increased the strin-
gencyofour validationefforts.Whenusingacutoff of 20%change
in the p21:PUMA protein ratio relative to a nontargeting shRNA
control, this assay led to the identification of 12 genes whose
knockdown tips the balance toward more PUMA (e.g., TCF3/
E2A,C3orf60,GPR110) and seven geneswith the opposite effect
(e.g., TRIAP1, GSPT1, POSTN) (Figures 1E and S1E; Table S2).1348 Cell Reports 3, 1346–1354, May 30, 2013 ª2013 The AuthorsFrom these validation efforts, we selected two factors for
further study, TCF3/E2A and TRIAP1, whose depletion produced
themost pronounced changes in p21:PUMA expression. Knock-
down of TCF3/E2A with three different shRNAs leads to
decreased p21 induction and increased PUMA expression
upon Nutlin-3 treatment, without affecting p53 accumulation
(Figure 1E). In contrast, depletion of TRIAP1 with three different
shRNAs leads to stronger p21 induction with negligible effects
on PUMA expression or p53 accumulation. Thus, TCF3/E2A
works concurrently as a coactivator of p21 and repressor of
PUMA, while TRIAP1 behaves as a gene-specific repressor of
p21 (Figure 1E, diagram).
Taken together, these results demonstrate that our genetic
screen successfully identified regulators of the p21:PUMA
expression ratio, which could potentially modulate the cellular
response to p53 activation.
TCF3/E2A and TRIAP1 Are Conserved Specific
Coregulators of the p21:PUMA Expression Ratio
The cellular response to p53 activation varies greatly across cell
types. Several gene-specific regulators of p53 target genes have
been identified, but their action is often restricted to specific cell
types (Sullivan et al., 2012a; Vousden and Prives, 2009). In order
to test for the conservation of TCF3/E2A and TRIAP1 effects, we
defined their impact across three cancer cell types of diverse tis-
sue origins during a time course of Nutlin-3 treatment between 6
and 48 hr. Importantly, TCF3/E2A knockdown leads to
decreased p21 induction and increased PUMA expression in
HCT116 cells (colorectal carcinoma), U2OS cells (osteosar-
coma), and A549 cells (lung carcinoma) at multiple time points
(Figures 2A and S2A). Of note, TCF3/E2A depletion had no sig-
nificant effects on the extent and kinetics of p53 accumulation,
suggesting that this factor acts downstream or in parallel to
p53. Interestingly, TCF3/E2A expression decreases upon Nut-
lin-3 treatment in all three cell types tested, but not in HCT116
p53/ cells (Figures 2A, S2A, and S2C). Of note, TCF3/E2A
levels are also downregulated over prolonged time in cell culture
regardless of p53 status, which correlates with decreased prolif-
eration rates (Figures S2C and S2D), and this downregulation is
also observed at the mRNA level (Figures S2E and S2F). Overall,
these results indicate that TCF3/E2A expression is higher in
proliferating cells and downregulated by p53-dependent and -in-
dependent cell-cycle arrest. Next, we investigated the effect of
TCF3/E2A depletion on expression of the p21 and PUMA
mRNAs using quantitative RT-PCR. In fact, TCF3/E2A knock-
down decreases p21 mRNA accumulation while enhancing
PUMA mRNA induction at multiple time points in every cell line
tested (Figure 2A and S2A). Of note, TCF3/E2A knockdown
also affects the basal expression levels of p21 mRNA (see Fig-
ure S2G for replotting of the basal expression data at a lower
scale). Interestingly, TCF3/E2A does not affect the induced
expression of several additional p53 target genes in various
functional pathways, thus demonstrating its highly specific ef-
fects toward p21 and PUMA in this setting (Figure 2C). Alto-
gether, our results demonstrate that TCF3/E2A is a conserved
and specific coregulator of the p21:PUMA expression ratio
upon p53 activation acting primarily at the mRNA expression
level.
Figure 2. TCF3/E2A and TRIAP1 Control the p21:PUMA Expression Ratio in Diverse Cancer Cell Types
(A) Western blot and qRT-PCR assays show that TCF3/E2A functions as a coactivator of p21 expression and a repressor of PUMA expression in HCT116
colorectal carcinoma cells and U2OS osteosarcoma cells. See Figure S2 for data on A549 lung carcinoma cells.
(B) TRIAP1 functions as a gene-specific repressor of p21.
(C and D) qRT-PCR analysis showing the effects of TCF3/E2A and TRIAP1 knockdown on diverse p53 target genes. All qRT-PCR experiments are expressed as
averages of three biological replicates ± SD.
See also Figure S2.TRIAP1 was previously characterized as a p53 target gene
with prosurvival functions (Park and Nakamura, 2005). Indeed,
we observed increased TRIAP1 expression upon p53 activation
in HCT116, U2OS, and A549 cells (Figures 1E, 2B, and S2B).
TRIAP1 was identified in our screen as a factor whose depletion
leads to a higher p21:PUMA ratio. In fact, TRIAP1 knockdown
increased p21 protein levels in all three cell lines tested
throughout the time course of Nutlin-3 treatment (Figures 2BCand S2B). In contrast, PUMA expression was not affected by
TRIAP1 knockdown. As observed for TCF3, TRIAP1 does not
affect p53 accumulation. In HCT116 cells, qRT-PCR analysis
demonstrates that TRIAP1 depletion produces an increase in
p21 mRNA expression, both basal and induced, with no effects
on PUMA mRNA (Figures 2D and S2H). However, this effect on
p21 mRNA was not observed in U2OS and is weak in A549 cells
(Figures 2B and S2B), suggesting that TRIAP1may influence p21ell Reports 3, 1346–1354, May 30, 2013 ª2013 The Authors 1349
protein expression by multiple mechanisms. qRT-PCR analysis
of multiple p53 target genes in HCT116 cells showed that
TRIAP1 depletion leads to a modest but statistically significant
increase in the expression of 14-3-3s and TLR3 (Figure 2D).
Overall, these data indicate that TRIAP1 functions as a p53-
inducible repressor of p21 expression across diverse cancer
cell types.
TCF3/E2A Does Not Impair p53 Binding or RNAPII
Transactivation at the p21 Locus but Affects p21 mRNA
Stability
TCF3/E2A has been previously reported to be a positive regu-
lator of p21 expression (Prabhu et al., 1997), but its mechanism
of action has not been elucidated. Chromatin immunoprecipita-
tion (ChIP) analysis of the p21 locus demonstrates that TCF3/
E2A binds to the p21 locus with peak signals around the tran-
scription start site (Figure 3A). Expectedly, TCF3/E2A binding
is much reduced in shTCF3/E2A cells. A modest decrease in
TCF3/E2A binding is observed upon Nutlin-3 treatment, which
reflects the lower cellular levels of this factor in this condition
(Figures 2A and 3A). Importantly, p53 binding to the upstream
enhancers in the p21 locus is not affected by TCF3/E2A knock-
down, indicating that TCF3/E2A does not modulate p53 DNA
binding activity or chromatin accessibility (Figure 3B). Next, we
tested whether TCF3/E2A affects RNA polymerase II (RNAPII)
transactivation at the p21 locus. Toward this end, we performed
ChIP assays of total RNAPII, initiating RNAPII (i.e., phosphory-
lated on serine 5 of the C-terminal domain repeats, S5P) and
elongating RNAPII (serine 2 phosphorylated, S2P). In agreement
with previous reports (Beckerman et al., 2009; Gomes et al.,
2006), we observed that p53 activation leads to increased levels
of elongating RNAPII at the p21 locus, as denoted by higher
levels of total RNAPII preferentially in the intragenic region, as
well as marked increases in S5P- and S2P-RNAPII at the 50
and 30 ends of the gene, respectively (Figures 3C–3E). Interest-
ingly, TCF3/E2A depletion does not affect the basal or induced
levels of total, S5P- and S2P-RNAPII, indicating that this factor
is not required for p53-dependent transactivation of RNAPII at
the p21 locus. Intrigued by this result, we investigated whether
the impact of TCF3/E2A depletion on p21 mRNA expression
could be explained by effects on mRNA half-life. Indeed,
mRNA half-life assays demonstrate that the p21 mRNA is more
rapidly degraded in shTCF3/E2A cells, both before and after Nut-
lin-3 treatment (Figure 3F). This effect is specific, as the half-life
of the 14-3-3s (SFN) mRNA is not affected by TCF3/E2A deple-
tion. Overall, these results indicate that TCF3/E2A does not
affect p53 binding or RNAPII initiation or elongation, but acts
instead at downstream steps. This could be due to direct action
at the p21 locus to facilitate cotranscriptional RNA processing or
indirect action by affecting the expression of posttranscriptional
regulators of p21mRNA stability. Future studies will discriminate
among these possibilities.
TCF3/E2A Modulates Cell-Fate Choice upon p53
Activation by DNA Damage in a p21- and PUMA-
Dependent Fashion
The ultimate goal of our genetic screen was to identify strategies
tomanipulate the cellular response to p53 activation via the iden-1350 Cell Reports 3, 1346–1354, May 30, 2013 ª2013 The Authorstification of factors that modulate the p21:PUMA ratio. We found
that TRIAP1 represses p21 expression prior to p53 activation
(see Figure S2H for RNA data and S3A for protein). Accordingly,
we observed decreased levels of bromodeoxyuridine (BrdU)
incorporation upon TRIAP1 knockdown in HCT116 and U2OS
cells, indicative of slow cell-cycle progression, as well as
decreased doubling time of the cell cultures (Figures S3B and
S3C). Interestingly, TRIAP1 has been previously characterized
as a prosurvival factor (Park and Nakamura, 2005). In agreement
with this report, we found that TRIAP1 depletion leads to
increased levels of cell death upon DNA damage by doxorubicin
(Figure S3D). Thus, although TRIAP1 functions as a repressor of
p21, which is often considered an antiapoptotic factor, the over-
all effects of TRIAP1 on cellular viability cannot be solely ex-
plained by its effects on p21 expression.
Next, we focused our efforts on TCF3/E2A. Interestingly, in-
dependent previous work from our group identified TCF3 as a
candidate ‘‘Synthetic Lethal with Nutlin-3’’ gene whose
knockdown would sensitize cells to Nutlin-3-induced cell death
(Sullivan et al., 2012b). In fact, we confirmed that TCF3/E2A
depletion increases the apoptotic index upon Nutlin-3 treat-
ment (Figure S3E), which agrees with the observed decrease
in the p21:PUMA ratio. In order to further test the impact of
TCF3/E2A on cell-fate choice upon p53 activation, we em-
ployed doxorubicin, a topoisomerase II inhibitor commonly
used in the clinic that induces a DNA damage response leading
to a combination of p53/p21-dependent cell-cycle arrest and
p53/PUMA-dependent apoptosis (Bunz et al., 1998; Yu et al.,
2003). Using an isogenic panel of HCT116 cell lines of varied
p21 and PUMA status, we confirmed that p21 knockout signif-
icantly impairs the cell-cycle arrest response upon doxorubicin
treatment while sensitizing to apoptosis (Figures 4A and 4B). In
this system, PUMA knockout has no significant effects on cell-
cycle arrest but clearly decreases doxorubicin-induced
apoptosis (Figures 4A and 4B). Thus, the cellular response to
doxorubicin could be modulated by the p21:PUMA ratio. Impor-
tantly, TCF3/E2A depletion in HCT116 cells leads to a signifi-
cant increase in the number of apoptotic cells upon doxorubicin
treatment as measured by Annexin V staining without signifi-
cant effects on the basal levels of apoptosis (Figures 4C and
4E). This effect is also observed in U2OS cells (Figure S3F).
TCF3/E2A knockdown leads to decreased p21 expression,
increased PUMA induction and increased levels of active cas-
pase 3 at 24, 48, and 72 hr of doxorubicin treatment without
significant effects on p53 accumulation (Figure 4D). Since
TCF3/E2A could possibly modulate the expression of hundreds
of target genes in the genome beyond p21 and PUMA, we
decided to investigate to what extent its effects on cell-fate
choice are dependent on these two p53 target genes
(Figure 4E). Expectedly, p21 knockout increases the apoptotic
index upon doxorubicin treatment while PUMA knockout de-
creases it (compare y axis values for control shRNA cells). Inter-
estingly, TCF3/E2A knockdown further increases apoptosis in
p21/ and PUMA/ cells but has no significant effects in
the apoptotic index of the double-knockout cells. Thus, we
conclude that TCF3/E2A regulates the cell-fate choice upon
p53 activation by doxorubicin in a p21/PUMA-dependent
manner.
Figure 3. TCF3/E2A Affects p21 mRNA Stability
(A–E) TCF3/E2A binds to the p21 proximal promoter and its depletion does not affect p53 binding or RNAPII transactivation. ChIP analysis of the p21 locus with
antibodies against TCF3/E2A (A), p53 (B), total RNAPII (C), serine 5-phosphorylated RNAPII (S5P, D), and serine 2-phoshoryalted RNAPII (E), in HCT116 cells
expressing control shRNA of shRNA against TCF3/E2A, treated with DMSO or 10 mMNutlin-3 (24 hr). The p21 genemap is shown at the bottom, with black boxes
representing exons and the transcribed region highlighted by a gray box. Numbers at the bottom indicate the position of PCR amplicons used to analyze ChIP-
enriched DNA relative to the transcription start site. n indicates the number of ChIPs performed with each antibody.
(F) TCF3/E2A depletion decreases p21 mRNA half-life. mRNA half-life assays were performed for the p21 and 14-3-3s (SFN) mRNAs by collecting RNA samples
at the indicated times after Actinomycin D (ActD) treatment in HCT116 cells expressing control or TCF3/E2A shRNAs, treatedwith DMSOor 10 mMNutlin-3 (24 hr).
Asterisks indicate significant different (p < 0.05) between shControl and shTCF3/E2A samples treated with DMSO (blue) or Nutlin-3 (red) within a given time point.
Data are expressed as averages of three experiments ± SD.DISCUSSION
Pleiotropy is a hallmark of ubiquitously expressed master tran-
scriptional regulators such as p53, NF-kB, and various nuclear
hormone receptors, which participate in a plethora of cellular
processes by regulating genes involved in distinct functional
pathways. Accordingly, the cellular response elicited by activa-Ction of these regulators varies greatly with the context, and
such pleiotropy often becomes an obstacle to effectively har-
nessing their activities for therapeutic purposes. In the case of
p53, its pleiotropic character limits the therapeutic potential of
p53-activating agents. In theory, nongenotoxic MDM2/4 inhibi-
tors could be employed to treat the 11 million cancer patients
currently carrying tumors with wild-type p53, as these agentsell Reports 3, 1346–1354, May 30, 2013 ª2013 The Authors 1351
Figure 4. TCF3/E2A Controls the Cellular
Response to p53 Activation upon DNADam-
age in a p21/PUMA-Dependent Fashion
(A) BrdU incorporation assays demonstrate that
p21 is required for the cell-cycle arrest response
observed upon doxorubicin treatment (0.5 mM,
12 hr) in HCT116 cells.
(B) Apoptotic index assays show that p21 attenu-
ates p53/PUMA-dependent apoptosis in response
to doxorubicin treatment.
(C) TCF3/E2A knockdown increases the apoptotic
index of HCT116 cells upon doxorubicin treat-
ment.
(D) Western blot assays show that TCF3/E2A
depletion leads to a lower p21:PUMA ratio
concurrently with increased levels of activated
executioner caspase 3 upon doxorubicin treat-
ment.
(E) TCF3/E2A knockdown enhances the apoptotic
index only in cells expressing p21 and/or PUMA.
Data in (A), (B), (C), and (E) are expressed as av-
erages of three experiments ± SD. See also Fig-
ure S3.could trigger selective elimination of cancer cells via p53-depen-
dent apoptosis (Brown et al., 2009). However, these compounds
trigger p53-dependent apoptosis only in select cancer cell types
(Parı´s et al., 2008; Tovar et al., 2006). Thus, there is a clear need
to identify and characterize the molecular mechanisms defining
cell-fate choice in response to p53 activation. Here, we report
an experimental approach for the identification of pathway-spe-
cific coregulators within a transcriptional program.We employed
p53 as the master regulator of choice and its target genes
CDKN1A (p21) andBBC3 (PUMA) as the pathway-specific effec-
tors. Our efforts led to the discovery of many factors modulating
the p21:PUMA expression ratio, including TCF3/E2A and
TRIAP1.1352 Cell Reports 3, 1346–1354, May 30, 2013 ª2013 The AuthorsTCF3/E2A is a member of the class I
helix-loop-helix (HLH) transcription fac-
tors, or E proteins, not to be confused
with TCF7L1 (also commonly referred to
as TCF3, a member of the T cell factor/
lymphoid enhancer family of transcription
factors activated by b-catenin). E proteins
are encoded by three genes: TCF3 (E2A),
TCF12 (HEB), and TCF4 (E2-2) (de Pooter
and Kee, 2010). Additionally, the TCF3 lo-
cus encodes two highly similar splicing
variants of E2A, known as E12 and E47,
which were first cloned based on their
ability to bind an ‘‘E-box’’ sequence in
the immunoglobulin K (IgK) light-chain
enhancer (Murre et al., 1989). Although
E protein transcription factors are ubiqui-
tously expressed, they play unique
essential roles in B and T lymphocyte
development (de Pooter and Kee, 2010).
Mice lacking TCF3/E2A display profound
defects in B lymphopoiesis, decreasedthymus size, and development of aggressive T cell lymphomas
by 3–6months of age (Engel et al., 2001; Yan et al., 1997; Zhuang
et al., 1994). Interestingly, in the absence of TCF/E2A, hemato-
poietic stem cells (HSCs) and their progeny show increased
cell-cycle progression that has been linked to decreased expres-
sion of p21 and other CDK inhibitors (Semerad et al., 2009), thus
leading to eventual exhaustion of the HSC pool.
Although TCF3/E2A is widely expressed across tissues, its
roles outside the immune system are poorly understood. Previ-
ous studies have shown that TCF3/E2A binds several E-boxes
in the p21 proximal promoter region and drives p21 expression
in HeLa and HEK293T cells with no active p53 (Prabhu et al.,
1997). Here, we show that TCF3/E2A is required for full p21
induction upon p53 activation by both nongenotoxic and geno-
toxic agents in multiple cancer cell types expressing wild-type
p53. Thus, p53 and TCF3/E2A act coordinately to enforce p21
expression and cell-cycle arrest in response to p53-activating
agents. This effect is exquisitely gene specific, as TCF3/E2A
knockdown does not affect induction of many other p53 target
genes in diverse pathways. Interestingly, TCF3/E2A seems to
act at steps downstream of p53 binding to the p21 enhancers
and RNAPII transactivation at this locus, affecting instead p21
mRNA stability. Strikingly, TCF3/E2A also acts as a gene-spe-
cific repressor of PUMA. The PUMA locus has an unusual chro-
matin architecture with constitutive intragenic transcription and
internal chromatin boundaries defined by the insulator factor
CTCF (Gomes and Espinosa, 2010). We found that TCF3/E2A
binds at several sites within the PUMA locus (Z.A. and J.M.E.,
unpublished data). Of note, there is evidence that TCF3/E2A
can function as a transcriptional repressor in B cells (Greenbaum
et al., 2004). Future studies will focus on elucidating the molec-
ular mechanism by which TCF3/E2A exerts opposite effects on
p21 and PUMA expression.
We found that TCF3/E2A depletion leads to increased
apoptosis in response to doxorubicin treatment, suggesting
that increased expression of TCF3/E2Amay protect cancer cells
from the killing effects of this commonly used chemotherapeutic
agent. Indeed, TCF3/E2A is expressed at high levels in prostate
cancer cells where it confers resistance to doxorubicin-induced
apoptosis (Patel and Chaudhary, 2012). The TCF3 locus is a
common target of chromosome rearrangements in diverse leu-
kemias leading to E2A chimeric proteins. Interestingly, the
chimeric E2A-HLF transcription factor was shown to abrogate
p53-induced apoptosis in myeloid leukemia cells by an unde-
fined mechanism (Altura et al., 1998). Our observation that
TCF3/E2A is a repressor of PUMA may explain these observa-
tions and provide a mechanistic basis for the oncogenic proper-
ties of TCF3/E2A chimeras.
Very little is known about TRIAP1, a factor identified in our
screen as a specific repressor of p21. Interestingly, TRIAP1
was first characterized as a p53-inducible cell survival factor
(Park and Nakamura, 2005). Whereas knockdown of TRIAP1
leads to increased levels of cell death in response to doxorubicin
treatment, its overexpression protected against cell death. We
confirmed that TRIAP1 functions as a survival factor but also
found that TRIAP1 reduces basal p21 protein expression, thus
allowing for increased cell-cycle progression as measured by
BrdU incorporation (Figures S3A–S3C). We have also confirmed
that TRIAP1 is a p53-activated gene as seen by western blot
upon Nutlin-3 treatment in multiple cell types (Figures 2B and
S2B). Thus, TRIAP1 enables an incoherent feed-forward loop
within the p53 network, where p53 induces transcription of
both p21 and a p21 repressor. Curiously, whereas TRIAP1
repression of p21 could be explained by effects on p21 mRNA
accumulation in HCT116 cells, TRIAP1 seems to regulate p21
levels by other mechanisms in U2OS and A549 cells. Regardless
of mechanism, it is clear that the overall effects of TRIAP1 as a
prosurvival factor in the p53 network cannot be explained by
its function as a p21 repressor, but may be due to other roles.
In fact, TRIAP1 was previously found to interact with APAF1
and prevent activation of caspase 9 (Park and Nakamura,C2005). Thus, the inhibitory effect of TRIAP1 on apoptosome ac-
tivity may override its repressive effect on p21 expression.
In summary, our functional genomics approach has identified
several gene-specific regulators within the p53 network, which
opens up new research venues not only for defining their mech-
anism of action, but also for designing strategies for the manip-
ulation of the cellular response to p53 activation.
EXPERIMENTAL PROCEDURES
Cell Culture and Knockdown Cell Line Preparation
HCT116 cells were cultivated in McCoy’s medium (Sigma) and U2OS and
A549 cells in DMEM (Sigma) supplemented with 10% fetal bovine serum
and antibiotic-antimycotic mixture (Life Technologies). Nutlin-3 (Cayman)
was solubilized in DMSO and used at 10 mM; doxorubicin (Sigma) was used
at 0.5 mM. Individual knockdown cell lines were generated using Sigma
Mission shRNA lentiviral plasmids (pLKO.1-puro; see the Extended Experi-
mental Procedures) as described previously (Sullivan et al., 2012b).
Apoptotic Index, BrdU Incorporation, Proliferation, and Cell-Cycle
Profile Assays
For apoptosis assays, cells were treated with doxorubicin for 72 hr, and both
adherent and floating cells were collected by trypsinization and labeled with
Annexin-V-FITC (Invitrogen) and propidium iodide (10 mg/ml) for 15 min in
the dark at room temperature and analyzed by flow cytometry (BD Accuri
C6, Becton Dickinson). For BrdU incorporation analysis, cells were exposed
to doxorubicin for 12 hr. One hour prior to harvest, 1 mg/ml of BrdU was added
to the medium, and trypsinized cells were fixed in 70% ethanol. DNA denatur-
ation was performed for 10 min in 2 M HCl with 0.5% Triton X-100 at 37C. Af-
ter neutralization with 0.1MNaBO4, cells were labeled with anti-BrdU antibody
and analyzed by flow cytometry. See the Extended Experimental Procedures
for antibody information, proliferation assays, and cell-cycle profile analysis.
Student’s t test was used for statistical analysis.
Western Blotting
Protein samples were subjected to SDS-PAGE and transferred to polyvinyli-
dene fluoride membrane (Millipore). Following incubation in blocking solution
and with primary antibody (see the Extended Experimental Procedures for
antibody information), HRP-conjugated secondary antibodies and enhanced
chemiluminescence solution (Millipore) were used to visualize proteins of inter-
est. Alternatively, for the detection of p21:PUMA ratio, membranes were
stained with both antibodies simultaneously. After incubation with fluorescent
dye-labeled secondary antibodies, membranes were scanned by Li-Cor sys-
tem, and band intensities were quantified in Odyssey 3.0.30 software (Li-Cor).
qRT-PCR
Total RNA was extracted using TRIreagent (SIGMA), and template comple-
mentary DNA (cDNA) was prepared with the qScript cDNA Synthesis Kit
(Quanta Biosciences). cDNA (10 ng) was used per PCR with SYBR Green
PCR Master Mix (Applied Biosystems, ABI) and quantified with the Absolute
Quantification Method in 7900HT ABI instrument (see the Extended Experi-
mental Procedures for primer information).
See the Extended Experimental Procedures for shRNA screen strategy,
ChIP assays, and mRNA half-life assays.
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